市場調查報告書
商品編碼
925279

心肺負載試驗系統市場 - 成長,趨勢,預測 (2020 - 2025)

Cardiopulmonary Stress Testing Systems Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球心肺負載試驗系統市場在2020年∼2025年間,預測將以4.6%的年複合成長率擴大。需要複數的心血管疾病徵兆和心肺功能評估的心房纖維顫動盛行率上升,心臟病早期診斷的壓力測試的需求也在不斷提升。

本報告提供心肺負載試驗系統的世界市場調查,提供市場概要,各類型,終端用戶,各地區的市場趨勢,市場規模的變化與預測,市場促進·阻礙因素以及市場機會分析,競爭情形,主要企業的簡介等全面性資訊。

目錄<

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 成長要素
  • 阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 各產品類型
    • 壓力血壓計
    • 運動實驗系統
    • 壓力心電圖
    • 其他
  • 各終端用戶
    • 醫院
    • 專門診所
    • 門診病人手術中心
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • MGC Diagnostics Corporation
    • General Electric Company
    • Koninklijke Philips NV
    • Hill-Rom Holdings Inc
    • OSI Systems Inc
    • Cosmed Srl
    • Cardinal Health
    • Care Medical Ltd
    • Cardiac Science Corp
    • Thermo Fisher Scientific Ltd

第7章 市場機會及未來趨勢

目錄
Product Code: 67805

The Cardiopulmonary Stress Testing Systems Market studied was anticipated to grow with a CAGR of nearly 4.6%, during the forecast period. The major factors attributing to the growth are a rise in the global prevalence of multiple cardiovascular indications and atrial fibrillation necessitating the evaluation of Cardiopulmonary functioning. For instance, according to Global Health And Wellness Report - 2018, about 40% of the adult population in the United States have been diagnosed with a cardiovascular condition in 2018 demanding the adoption of stress testing procedures for early diagnosis of heart diseases driving the market growth throughout the forecast period.

Key Market Trends

Exercise Testing Systems are Expected to Hold the Largest Market Share

  • The Exercise Testing Systems attributes the largest share in the market owing to the accuracy and the least operating time taken by these devices. Furthermore, the increased preference by the physicians and patients due to their cost-effectiveness and multiple applications of these devices also contribute to the rise in the adoption of these systems fueling the growth of the market.
  • Based on the end-users, the hospital segment is expected to dominate the cardiopulmonary stress testing systems market. Dominance is due to the preference of patients for the early diagnosis of cardiovascular diseases as prescribed by physicians. The diagnostic centers are likely to witness the highest growth due to the adoption of advanced technologies in the developed countries driving the global cardiopulmonary stress testing systems market over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the global cardiopulmonary stress testing (CPST) systems market throughout the forecast period. The dominance is due to the rising prevalence of cardiovascular and pulmonary disorders such as arrhythmia, heart failures, ischemic heart disease, dyspnea and heart valve imbalance in the United States which generates higher demand for the CPST. For instance, according to the Journal of American Medical Association report - 2018, about 93.3 million adults over the age of 20 in the United States were obese which is the major cause for cardiopulmonary diseases driving the market growth in the forecast period. Also, increasing incidences of lifestyle diseases and enhanced awareness among the medical professionals about the advantages of CPST along with the availability of advanced healthcare infrastructure in the region contributes to its outstanding share in the global market revenue.

Competitive Landscape

The cardiopulmonary stress testing systems market is moderately competitive and consists of several major players. In terms of market revenue, few of the prominent players currently dominating the market are vigorously making acquisitions with the other companies to consolidate their market positions across the globe and while others are launching new products. For example, in August 2019, Vyaire Medical Inc received FDA clearance for its two Novel Pulmonary Function Testing Products Vyntus ONE and Vyntus BODY, expanded their existing Vyntus products portfolio which runs on the easy-to-operate SentrySuite Software. The approved products offer a modern ergonomic design, consistent and accurate respiratory testing attracting the attention of customers in the U.S. Healthcare contributing to the market growth. Some of the companies which are currently dominating the market are Koninklijke Philips N V, Hillrom Services Inc, General Electric Company, MGC Diagnostics Corporation, OSI Systems Inc.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in Global Healthcare Expenditure
    • 4.2.2 Rise in Global Prevalence of Cardiopulmonary Disorders
  • 4.3 Market Restraints
    • 4.3.1 Stringent FDA Regulations
    • 4.3.2 Higher Challenges During the Development Stage and Expensive Testing Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Product Type
    • 5.1.1 Stress Blood Pressure Monitors
    • 5.1.2 Exercise Testing Systems
    • 5.1.3 Stress ECG
    • 5.1.4 Others
  • 5.2 End-user
    • 5.2.1 Hospitals
    • 5.2.2 Specialty Clinics
    • 5.2.3 Ambulatory Surgical Centers
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 MGC Diagnostics Corporation
    • 6.1.2 General Electric Company
    • 6.1.3 Koninklijke Philips N V
    • 6.1.4 Hill-Rom Holdings Inc
    • 6.1.5 OSI Systems Inc
    • 6.1.6 Cosmed Srl
    • 6.1.7 Cardinal Health
    • 6.1.8 Care Medical Ltd
    • 6.1.9 Cardiac Science Corp
    • 6.1.10 Thermo Fisher Scientific Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS